Evidence map›Paper›PMID 31437536›Full record

ArticleNeoplasia (New York, N.Y.)2019

Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.

F R Saenz, V Ory, M O Schmidt, B V Kallakury, S C Mueller, P A Furth, A Wellstein, A T Riegel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

F R SaenzDepartment of Oncology, Georgetown University, Washington, DC, USA.
V OryDepartment of Oncology, Georgetown University, Washington, DC, USA.
M O SchmidtDepartment of Oncology, Georgetown University, Washington, DC, USA.
B V KallakuryDepartment of Pathology, Georgetown University, Washington, DC, USA; The Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
S C MuellerDepartment of Oncology, Georgetown University, Washington, DC, USA.
P A FurthDepartment of Oncology, Georgetown University, Washington, DC, USA; The Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA; Department of Medicine, Georgetown University, Washington, DC, USA.
A WellsteinDepartment of Oncology, Georgetown University, Washington, DC, USA; The Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
A T RiegelDepartment of Oncology, Georgetown University, Washington, DC, USA; The Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Electronic address: ariege01@georgetown.edu.
Georgetown University · USGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast CancerR01CA205632 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2016 to 2020
$2.3M
Development of clinically relevant models of DCISR21CA226542 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2019 to 2020
$369k
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA205632NCI NIH HHS R21 CA226542NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

The transcriptional coactivator Amplified in Breast Cancer 1 (AIB1) plays a major role in the progression of hormone and HER2-dependent breast cancers but its role in triple negative breast cancer (TNBC) is undefined. Here, we report that established TNBC cell lines, as well as cells from a TNBC patient-derived xenograft (PDX) that survive chemotherapy treatment in vitro express lower levels of AIB1 protein. The surviving cell population has an impaired tube-formation phenotype when cultured onto basement membrane, a property shared with TNBC cells that survive shRNA-mediated depletion of AIB1 (AIB1

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell Line, TumorClonal EvolutionDisease Models, AnimalExome SequencingFemaleGene Expression ProfilingHeterograftsHumansMiceNuclear Receptor Coactivator 3PhenotypeRNA, Small InterferingSignal TransductionTranscriptomeNCOA3 protein, humanNuclear Receptor Coactivator 3RNA, Small Interfering

Identifiers

PMID31437536
PMCPMC6706655
OpenAlexW2969248461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.